阿魏酸钠治疗不稳定型心绞痛160例疗效观察

目的　观察阿魏酸钠 (SF)治疗不稳定型心绞痛 (UAP)的临床疗效。方法　将 160例患者随机分为 :对照组 (80例 )按UAP常规治疗 ,观察组 (80例 )在常规治疗的基础上加SF治疗 ,观察比较两组的疗效。结果　与对照组相比 ,观察组心绞痛症状及静息心电图的改善均非常显著 (P <0 .0 1) ,无明显药物不良反应。结论　在常规治疗基础上加用SF ,对UAP有显著疗效。     

阿托伐他汀联合胺碘酮治疗原发性高血压伴阵发性房颤的研究

目的 探讨阿托伐他汀治疗原发性高血压伴阵发性心房颤动的疗效及对左心房内径、C反应蛋白(CRP)的影响.方法 入选原发性高血压伴阵发性心房颤动患者80例,随机分成两组:对照组40例;阿托伐他汀组40例.均服药1年.观察两组治疗前后疗效及左心房内径、C反应蛋白的变化.结果 ①两组治疗后,对照组有效率38.4%,阿托伐他汀组有效率62.5%(x2=4.56 P<0.05);②两组治疗后比较,阿托伐他汀组左心房内径增大程度低于对照组(P<0.05),血CRP浓度比对照组降低明显(P<0.05).结论 阿托伐他汀能通过抗炎、抑制左心房重构作用预防阵发性心房颤动复发.     

吡格列酮对无胰岛素抵抗的原发性高血压患者左心室肥厚及炎性因子的影响

目的探讨吡格列酮对无胰岛素抵抗的原发性高血压患者左心室肥厚及炎性因子的影响。方法选择无胰岛素抵抗的原发性高血压伴左心室肥厚患者60例,随机分成吡格列酮组与常规治疗组。常规治疗组给予依那普利治疗,吡格列酮组给予依那普利和吡格列酮治疗,均治疗6个月。比较两组患者治疗前后左心室质量指数（LVMI）、血清肿瘤坏死因子α（TNF-α）、白介素1β（IL-1β）和白介素6（IL-6）的变化水平。结果吡格列酮组与常规治疗组患者治疗前LVMI、血清TNF-α、IL-1β、IL-6的水平比较,差异均无统计学意义（P〉0.05）,两组患者治疗后LVMI、血清TNF-α、IL-1β、IL-6的水平比较,差异均有统计学意义（P〈0.05）。结论吡格列酮能通过抗炎作用逆转原发性高血压左心室肥厚。     

氯吡格雷联合阿司匹林治疗不稳定性心绞痛疗效观察

不稳定型心绞痛是一组严重的临床综合征。正确的诊断和及时有效的治疗将在很大程度上改善患者的预后。不稳定型心绞痛的病理基础和重要原因在于粥样斑块的破裂和血栓形成，血小板活化是血栓形成的重要原因。因此，抗血小板治疗能极其有效地预防不稳定型心绞痛的并发症。试验证明，应用阿斯匹林(ASA)可降低心脏性死亡及非致命心肌梗死的发生率。本研究旨在于探讨阿司匹林联合应用氯吡格雷治疗不稳定型心绞痛的疗效。     

宿主因子NF90调节流感病毒复制的研究

【目的】 研究流感病毒的宿主因子NF90对流感病毒复制的影响。 【方法】 从 293T细胞中提取总RNA,以Oligo(dT)反转录cDNA。根据Gen Bank 中NF90的基因序列,设计上下游引物。以转录出的cDNA为模板扩增出NF90基因。用EcoR I 和Not I两种核酸内切酶对NF90 PCR扩增产物和PCDNA3.1-V5-HIS载体进行双酶切,酶切产物用高效DNA连接酶连接,然后鉴定选取正确的重组质粒,并命名为PCDNA3.1-NF90-V5-HIS。把PCDNA3.1-NF90-V5-HIS重组质粒转染至293T细胞,转染36 h后感染流感病毒A/WSN/1933 Moi 0.01,感染16 h后提取293T细胞的总蛋白,用蛋白质印迹法检测PCDNA-NF90-V5-HIS 重组质粒和流感病毒NP蛋白的表达。 【结果】 PCDNA3.1-NF90-V5-HIS重组质粒转染至细胞后,NP蛋白表达下降,流感病毒复制减弱。 【结论】 宿主因子NF90可以抑制流感病毒的复制。     

曲美他嗪治疗不稳定型心绞痛

目的 探讨曲美他嗪治疗不稳定型心绞痛(UAP)的临床疗效及对内皮素(ET)、一氧化氮(NO)的表达影响.方法 随机选择UAP患者80例,入选患者被随机单盲分为曲美他嗪组40例和常规治疗组40例.观察统计两组治疗前1周和治疗结束后1周心绞痛发作次数、自拟的疼痛强度及持续时间记分值,检测治疗前后患者血浆ET和NO水平的变化.结果 曲美他嗪组和常规治疗组比较,治疗后患者疼痛发作频率、疼痛强度及持续时间记分均有明显减少,但曲美他嗪组的疗效比常规治疗组明显,差异有统计学意义(P<0.05). 两组治疗都可改善不稳定型心绞痛患者心电图ST段的偏移,但曲美他嗪组的疗效比常规治疗组显著, 差异有统计学意义(P<0.05).两组都可改善心绞痛患者心电图表现,但差异无统计学意义(P>0.05).两组患者治疗后血浆ET水平明显减低,NO水平明显升高,但曲美他嗪组比常规治疗组显著, 差异有统计学意义(P<0.01).结论 曲美他嗪组对不稳定型心绞痛患者疗效明显升高,这种疗效与改善血管内皮细胞功能有关. Abstract： Objective To observe the effects of trimetazidine on plasma concentration of endothelin(ET) and nitric oxide(NO) in patients with unstable angina pectoris(UAP).Methods Randomly selected 80 patients with unstable angina pectoris, patients were randomly divided into trimetazidine group with 40 patients, and conventional treatment group with 40 patients. The clinical effect was observed by the changes of the angina pectoris frequencies and pain period and intensity score per mean day at 1 week pro-treatment and 1 week post-treatment. Plasma concentrations of ET and NO were measured before and after the treatment.Results The frequency, intensity and duration of pain score was significantly reduced in both groups, and the effect of trimetazidine group was obvious than the conventional treatment group, the difference was statistically significant(P<0.05). The two groups can improve the treatment of unstable angina patients ECG ST section of the shift, and the effect of trimetazidine group was obvious than the conventional treatment group, the difference was statistically significant(P<0.05). Two groups of patients can improve angina and ECG, but the difference was not statistically significant(P>0.05). In the two groups, plasma ET was significantly reduced, and plasma NO was significantly elevated,the effect of trimetazidine group was obvious than the conventional treatment group, the difference was statistically significant(P<0.01).Conclusions The effects of trimetazidine on patients with unstable angina pectoris is significantly elevated, and is significantly beneficial to protect the endothelial function.     

复方丹参滴丸治疗冠心病心绞痛100例疗效观察

目的 :观察复方丹参滴丸对冠心病心绞痛的疗效。方法 :治疗组 10 0例给予复方丹参滴丸 10粒 /次 ,每日 3次口服 ,疗程 4周 ,观察用药后冠心病心绞痛患者的症状缓解及心电图变化情况。并设同期服用复方丹参片者 10 0例 ,每次 3片 ,每日 3次为对照组。结果 :服用复方丹参滴丸者 ,胸闷、心绞痛症状缓解率达 90 % ,对照组缓解率达 60 %(P<0 .0 1) ,心电图好转率 76.2 % ,对照组为 46.7% (P<0 .0 5 )。结论 :复方丹参滴丸疗效确切 ,服用方便 ,长期服用无不良反应 ,值得临床推广应用     

曲美他嗪联合阿托伐他汀治疗原发性高血压伴阵发性心房颤动的疗效观察

Objective To study the efficacy of trimctazidine combined with atorvastatin for primary hypertension with paroxysmal auricular fibrillation,and its effects on LAD and CRP. Methods 160 patients of pri-mary hypertension with paroxysmal auricular fibrillation were randomly divided into 4 groups. Forty patients were treated with amiodarone (control group),600 mg/d for the first week,400 mg/d for the second week and 200 mg/d later;40 patients were treated with atorvastatin (20 mg/d,3 times per day) in addition to amiodarone (the atorvasat-in group);40 patients were treated with trimetazidine (20 mg/d,3 times per day) in addition to armiodarone (the trimetazidine group);40 patients were treated with combination of trimetazidine and atorvastatin in addition to amiod-atone (the combination group),and the dose was the same as the above groups. The treatment was started within 24 hours of recovering from paroxysmal auricular fibrillation and lasted for 1 year. Results After 1 year there was 1 pa-the control group,and 62.5% (25/40) for the atorvasatin group,64.1% (25/39) for the trimetazidine group,and 84.6% (33/39) for the combination group. Compared to the control group,the effective rate of the 3 treatment groups were all significantly higher (X2=4.56、5.13、17.55,P<0.05). The effective rate of the combination group was significantly higher than that of the atorvasatin group and the trimetazidine group (X2=4.95、4.30,P<0.05),and there was no significant difference of effective rate between the atorvasatin group and the trimetazidine group(X2= >0.05). After treatment LAD was (40.96+1.81) mm in the control group,(38.65±1.90) mm in the atorvasatin group,(39.15±1.85)mm in the trimetazidine group,and (37.22±1.74) mm in the combination group. LAD of the 3 treatment groups were all significantly different from the control group(F=3.42,P<0.05). LAD of the combina-tion group was significantly smaller than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no significant difference of the LAD between the atorvasatin group and the trimetazidine group(P>0.05). There was no significant difference between the 4 groups on CRP before treatment (F=0.96,P>0.05). After treat-ment CRP was (8.85±1.45) mg/L in the control group,(5.96±1.26) mg/L in the atorvasatin group,(6.81± 1.37) mg/L in the trimetazidine group,and (3.75±1.15) mg/L in the combination group. CRP of the 3 treatment groups were all significantly different from the control group (F=3.63,P<0.05). CRP of the combination group was significantly lower than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no signif-icant difference of CRP between the atorvasatin group and the trimetazidine group (P>0.05). Conclusion The treatment with trmetazidine combined with atorvastatin could prevent recurrence of paroxysmal auricular fibrillation though anti-inflammatory and inhibiting the remodeling of left atrial.     

急性心肌梗死患者经皮介入治疗后血小板α-颗粒膜蛋白和内皮素的变化及意义

急性心肌梗死（AMI）早期予以经皮介入治疗（PCI）能明显降低病死率,但PCI后6个月内血管再狭窄率约20%～30%左右.因此,及早发现预测冠状动脉（冠脉）再狭窄,并采取有效措施预防,则可改善其预后.冠脉再狭窄的形成与血小板聚集、活性增高和内皮下平滑肌细胞过度增殖有关.我们旨在探讨AMI患者急诊PCI后血小板α-颗粒膜蛋白（GMP-140）及内皮素（ET1）的动态变化及其临床意义.     

COPD急性加重期并发呼吸道病毒感染的影响因素

目的 探讨慢性阻塞性肺疾病(COPD)急性加重期患者呼吸道病毒感染的影响因素,并对患者外周血单个核细胞(PBMCs)中微小RNA-206(miR-206)表达水平进行分析。方法 选取2018年1月-2020年12月四川省人民医院收治的COPD急性加重期患者104例,收集患者痰液样本,使用荧光定量聚合酶链式反应(RT-PCR)对样本中17种呼吸道病毒进行检测;单因素及多因素Logistic回归分析COPD急性加重期患者呼吸道病毒感染的影响因素;受试者工作特征曲线(ROC)评价PBMCs miR-206表达水平对COPD急性加重期患者呼吸道病毒感染的评估价值。结果 104例COPD急性加重期患者中,呼吸道病毒检测阳性33例占31.73%。共检出病毒42株,以鼻病毒感染为主,占26.19%,其次为流感病毒乙型,占21.43%。多因素Logistic回归分析显示,糖尿病、近1年内急性加重次数≥3次、miR-206表达水平均为COPD急性加重期患者呼吸道病毒感染的影响因素。ROC分析显示,miR-206表达水平评估COPD急性加重期患者呼吸道病毒感染截断值为0.085,AUC为0.881(95%...